Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
Agenus (AGEN) is back in focus after reporting three year Phase 1b data for its BOT+BAL immunotherapy in refractory microsatellite stable metastatic colorectal cancer, alongside an oversubscribed private placement tied to its registrational ROBBIN trial.
See our latest analysis for Agenus.
The BOT+BAL data and oversubscribed financing come after a sharp shift in sentiment toward Agenus, with a 7 day share price return of 54.32% and a 30 day share price return of 67.79%, even as the 1 year total shareholder return is down 25.60% and the 5 year total shareholder return is down 95.43%. This signals short term momentum against a weaker long term record.
If this kind of clinical and financing news has your attention, it can also be worth scanning other oncology focused opportunities, starting with our healthcare AI stock ideas in the 39 healthcare AI stocks.
After a 67.79% 30-day surge and a long-term record that is still deeply in the red, Agenus now trades at a steep discount to analyst targets. Is that discount caution well placed or too heavy handed given recent data and funding?
Most Popular Narrative: 83.3% Undervalued
The most followed narrative on Agenus pegs fair value at $30 per share compared with the recent $5 close, highlighting a sharp valuation gap driven by its colorectal cancer focus and funding story.
Surging global incidence and earlier onset of colorectal cancer, coupled with significant unmet need among patients with microsatellite stable (MSS) “cold” tumors who currently lack effective immuno oncology options, support a substantial and expanding addressable market for Agenus’ therapies. This is likely to drive top line revenue growth as new indications are approved.
Curious how a company with flat revenue assumptions and shrinking earnings still lands a high fair value? The narrative leans heavily on future margins, premium valuation multiples and a concentrated earnings profile around botensilimab and balstilimab. The full set of assumptions may surprise you.
Result: Fair Value of $30 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, the Agenus narrative still leans on unproven BOT+BAL outcomes in larger Phase 3 settings and continued funding needs that could lead to further dilution.